| Business Summary | | Hemosol,
Inc.
is
an
integrated
biopharmaceutical
company
developing
a
multi-product
pipeline
for
global
markets
based
on
proprietary
technologies
for
use
initially
in
the
treatment
of
hemoglobin
deficiencies.
Hemosol
has
a
broad
range
of
products
in
development
which
include:
hemoglobin
based
oxygen
carriers
(HBOCs)
including
Hemolink;
hemoglobin
therapeutics
to
treat
a
variety
of
diseases
such
as
reperfusion
injury,
hepatitis
C
and
cancers
of
the
liver;
and
cell
therapy
for
the
treatment
of
cancer
and
infectious
disease.
The
Company
also
is
developing
methods
to
harvest
hemoglobin,
from
cells
grown
and
expanded
under
controlled
manufacturing
conditions
outside
of
the
human
body. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Hemosol,
Inc.
is
an
integrated
biopharmaceutical
company
developing
a
multi-product
pipeline
for
global
markets
based
on
propietary
technologies,
used
initially
in
the
treatment
of
hemoglobin
deficiencies.
For
the
three
months
ended
3/30/01,
the
Company
reported
no
revenues.
Net
loss
rose
22%
to
C$6.9
million.
Higher
loss
reflects
higher
clinical,
regulatory,
scientific
and
process
R&D
expenditures
and
higher
administration,
marketing
and
business
development
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
after
tax
earnings
were
-14,042. (Preliminary; reported in thousands of Canadian Dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Edward Rygiel | Chairman | John Kennedy | Pres,
CEO, Director | Lee Hartwell | CFO,
VP, Corp. Devel. | Dirk Alkema, Ph.D. | VP-Operations
and Regulatory Affairs | Lee Malcolm | VP
of Marketing |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|